Suggested remit: To appraise the clinical and cost effectiveness of delgocitinib within its marketing authorisation for treating moderate to severe chronic hand eczema.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6408

Project Team

Project lead Vonda Murray

Email enquiries

Stakeholders

Companies sponsors Leo Pharma
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
Patient carer groups Allergy UK
  Black Health Agency for Equality
  Changing Faces
  Eczema Outreach Support
  Let’s face it
  National Eczema Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Allergy UK
  Black Health Agency for Equality
  Changing Faces
  Eczema Outreach Support
  Let’s face it
  National Eczema Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
Assessment group National Institute for Health Research Health Technology Assessment Programme (NETSCC)
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AAH Pharmaceuticals (alitretinoin, tacrolimus)
  Accord UK (tacrolimus)
  Advanz Pharma (methotrexate)
  Aspen (azathioprine, mycophenolate mofetil)Cipla UK (methotrexate)
  Dexcel Pharma (ciclosporin)
  Ennogen Healthcare (alitretinoin)
  GlaxoSmithKline (alitretinoin)
  Hospira (methotrexate)
  Leo Pharma (tacrolimus)
  Medac (methotrexate)
  Medihealth (tacrolimus)
  Morningside Healthcare (methotrexate)
  Mylan (azathioprine; ciclosporin, mycophenolate mofetil)
  Nordic Pharma (methotrexate)
  Nova (azathioprine; mycophenolate mofetil)
  Novartis (ciclosporin)
  Orion Pharma (methotrexate)
  Rosemont Pharmaceuticals (methotrexate)
  Sandoz (methotrexate)
  Santen UK (ciclosporin)
  Strides Pharma (azathioprine, mycophenolate mofetil)
  Teva UK (tacrolimus)
  Tillomed Laboratories (azathioprine, mycophenolate mofetil)
  Viatris (pimecrolimus)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Centre of Evidence-based Dermatology, University of Nottingham
  Cochrane Skin Group
  Dermatrust
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
22 October 2024 Invitation to participate
17 July 2024 - 14 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 July 2024 In progress. Scoping commencing
31 January 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
30 January 2024 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual